Estrella Immunopharma Inc
ESLA1.690USD
+0.110+6.96%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
63.82MMarket Cap
LossP/E TTM
More Details of Estrella Immunopharma Inc Company
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
Estrella Immunopharma Inc Info
Ticker SymbolESLA
Company nameEstrella Immunopharma Inc
IPO dateJul 19, 2021
CEOLiu (Cheng)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJul 19
Address5858 Horton St, Suite 370
CityEMERYVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94608
Phone15103189098
Websitehttps://www.estrellabio.com/
Ticker SymbolESLA
IPO dateJul 19, 2021
CEOLiu (Cheng)
Company Executives of Estrella Immunopharma Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Hong Zhang
Ms. Hong Zhang
Chairman of the Board
Chairman of the Board
240.48K
--
Ms. Pei Xu
Ms. Pei Xu
Independent Director
Independent Director
--
--
Dr. Cheng Liu, Ph.D.
Dr. Cheng Liu, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Xu
Mr. Peter Xu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Marsha Roberts
Dr. Marsha Roberts
Independent Director
Independent Director
--
--
Mr. Fan Wu
Mr. Fan Wu
Independent Director
Independent Director
--
--
Ms. Janelle Wu
Ms. Janelle Wu
Independent Director
Independent Director
--
--
Mr. Jia Dengyao
Mr. Jia Dengyao
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Hong Zhang
Ms. Hong Zhang
Chairman of the Board
Chairman of the Board
240.48K
--
Ms. Pei Xu
Ms. Pei Xu
Independent Director
Independent Director
--
--
Dr. Cheng Liu, Ph.D.
Dr. Cheng Liu, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Xu
Mr. Peter Xu
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Marsha Roberts
Dr. Marsha Roberts
Independent Director
Independent Director
--
--
Mr. Fan Wu
Mr. Fan Wu
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Eureka Therapeutics Inc
66.93%
The Vanguard Group, Inc.
1.11%
Liu (Cheng Ph.D.)
0.79%
Xu (Jiandong Peter)
0.70%
Zhang (Hong)
0.64%
Other
29.83%
Shareholders
Shareholders
Proportion
Eureka Therapeutics Inc
66.93%
The Vanguard Group, Inc.
1.11%
Liu (Cheng Ph.D.)
0.79%
Xu (Jiandong Peter)
0.70%
Zhang (Hong)
0.64%
Other
29.83%
Shareholder Types
Shareholders
Proportion
Corporation
66.93%
Individual Investor
2.12%
Investment Advisor
1.41%
Investment Advisor/Hedge Fund
0.33%
Hedge Fund
0.20%
Venture Capital
0.03%
Other
28.97%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
17
771.69K
1.75%
--
2025Q3
19
771.69K
2.50%
+136.87K
2025Q2
25
634.82K
3.13%
+21.67K
2025Q1
25
613.14K
2.27%
-208.49K
2024Q4
31
292.28K
2.97%
+92.18K
2024Q3
42
200.09K
8.78%
+55.37K
2024Q2
43
126.75K
8.78%
-12.18K
2024Q1
39
138.90K
8.70%
-3.04M
2023Q4
38
128.58K
8.69%
-158.51K
2023Q3
39
287.09K
12.16%
-469.48K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Eureka Therapeutics Inc
25.28M
68.2%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
282.84K
0.76%
+5.26K
+1.90%
Jun 30, 2025
Liu (Cheng Ph.D.)
297.44K
0.8%
--
--
Dec 31, 2024
Xu (Jiandong Peter)
264.39K
0.71%
--
--
Dec 31, 2024
Zhang (Hong)
240.48K
0.65%
--
--
Dec 31, 2024
Geode Capital Management, L.L.C.
103.34K
0.28%
+3.16K
+3.16%
Jun 30, 2025
UBS Financial Services, Inc.
72.77K
0.2%
+31.74K
+77.35%
Jun 30, 2025
Citadel Advisors LLC
50.16K
0.14%
-41.44K
-45.24%
Jun 30, 2025
ATW Spac Management LLC
40.00K
0.11%
--
--
Jun 30, 2025
State Street Investment Management (US)
22.35K
0.06%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Estrella Immunopharma Inc?
The top five shareholders of Estrella Immunopharma Inc are:
Eureka Therapeutics Inc holds 25.28M shares, accounting for 68.20% of the total shares.
The Vanguard Group, Inc. holds 282.84K shares, accounting for 0.76% of the total shares.
Liu (Cheng Ph.D.) holds 297.44K shares, accounting for 0.80% of the total shares.
Xu (Jiandong Peter) holds 264.39K shares, accounting for 0.71% of the total shares.
Zhang (Hong) holds 240.48K shares, accounting for 0.65% of the total shares.
Eureka Therapeutics Inc holds 25.28M shares, accounting for 68.20% of the total shares.
The Vanguard Group, Inc. holds 282.84K shares, accounting for 0.76% of the total shares.
Liu (Cheng Ph.D.) holds 297.44K shares, accounting for 0.80% of the total shares.
Xu (Jiandong Peter) holds 264.39K shares, accounting for 0.71% of the total shares.
Zhang (Hong) holds 240.48K shares, accounting for 0.65% of the total shares.
What are the top three shareholder types of Estrella Immunopharma Inc?
The top three shareholder types of Estrella Immunopharma Inc are:
Eureka Therapeutics Inc
The Vanguard Group, Inc.
Liu (Cheng Ph.D.)
Eureka Therapeutics Inc
The Vanguard Group, Inc.
Liu (Cheng Ph.D.)
How many institutions hold shares of Estrella Immunopharma Inc (ESLA)?
As of 2025Q4, 17 institutions hold shares of Estrella Immunopharma Inc, with a combined market value of approximately 771.69K, accounting for 1.75% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.74%.
What is the biggest source of revenue for Estrella Immunopharma Inc?
In --, the -- business generated the highest revenue for Estrella Immunopharma Inc, amounting to -- and accounting for --% of total revenue.
